MorphoSys AG — Investor Presentation 2012

Mar 2, 2012

Year End Results 2011 & Outlook

Safe Harbour

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Contents

• Review 2011
• Pipeline
• Technology
• AbD Serotec
• Financials
• Financial Outlook 2012
• Operational Outlook 2012
• Pipeline
• Technology
• AbD Serotec

Pipeline

MorphoSys Pipeline Continues to Grow & Mature

Clinical Pipeline Increased by Three Programs

Number of clinical development programs in our pipeline

MorphoSys's Proprietary Programs in Clinical Trials (I)

Data in Q3 2012

Data in 2013

GM-CSF: A Novel Target Gaining Importance in RA & MS

Mavrilimumab program provides clinical validation of pathway

Two independent studies confirm view of GM-CSF as key cytokine in MS

MorphoSys's Proprietary Programs in Clinical Trials (II)

Progress in Early Programs

1 program

1 program

Clinical Antibody Pipeline

Program	Partner	Indication	Discovery	Pre-clinic	Phase 1	Phase 2
MOR103 (2 programs)	own	Rheumatoid arthritis, Multiple sclerosis
not disclosed	Novartis	not disclosed
CNTO888 (2 programs)	Janssen/J&J	Cancer IPF
Gantenerumab	Roche	Alzheimer's Disease
BHQ880	Novartis	Cancer
BYM338	Novartis	Musculoskeletal
CNTO 1959	Janssen/J&J	Psoriasis
not disclosed	Novartis	Ophthalmology				New!
MOR202	own	Cancer
MOR208	own	Cancer
CNTO 3157	Janssen/J&J	Asthma
not disclosed	Janssen/J&J	Inflammation
not disclosed	Novartis	Inflammation
not disclosed	Boehringer Ingelheim	Cancer
not disclosed	Pfizer	Cancer
OMP-59R5	Oncomed	Cancer
OMP-18R5	Oncomed	Cancer
BAY94-9343 (ADC)	Bayer HealthCare	Cancer

Progress in 2011 Progress in 2012 Not shown: 24 in pre-clinic

32 in discovery

Gantenerumab: First Clinical Data Supports Approach in AD

• First imaging data confirms Aβ plaque clearance
• 360 patients in Phase 2 trial in 100 centers in 19 countries

• Roche focuses on early Alzheimer's disease intervention

• Bapineuzumab and solanezumab data

• Gantenerumab and bapineuzumab in independent trial

Technology

MorphoSys's Next Generation Platform Ylanthia

AbD Serotec

Growing Focus on Diagnostics

First diagnostic HuCAL-based kits entered the market

Diagnostic HuCAL Products

Disease	Partner	Antibody Generation	Development	Regulatory Approval	Market
Autoimmune	Phadia
Autoimmune Disease	Proteomika
Rheumatoid Arthritis	Proteomika
Rheumatoid Arthritis	Proteomika
Cancer	Proteomika
Maternal Healthcare	n.d.
Immune Suppression	n.d.
Diabetes	n.d.
Infectious Disease	n.d.
Malaria	FIND
Cardiac	n.d.
Cancer	n.d.

Slonomics – New Opportunities for AbD Serotec in Industrial Biotechnology Applications

Financials

Double-digit Growth in Key Financials

FY2011: Income Statement

in € million	2011	2010	Change
Revenues	100.8	87.0	+16%
Cost of Goods Sold	7.0	7.3
Total Research and Development Expenses	57.5	46.9
Sales, General & Administrative Expenses	24.6	23.2
Total Operating Expenses	89.1	77.4	+15%
Other Operating Income	0.5	0.2
Profit from Operations	12.2	9.8	+24%
Finance Income	1.4	4.1
Other Expenses	2.1	0.8
Profit before Taxes	11.4	13.2	-14%
Income Tax Expenses	3.2	4.0
Net Profit	8.2	9.2	-11%
EPS (diluted)	0.36	0.40

Composition of Group Revenues

• Success-based Payments
• Proprietary Development
• License Fees and R&D Funding
• AbD Serotec

Five-Year Overview: Solid Financial Situation

Substantial Investment Into Proprietary R&D

in € million

Split of MorphoSys's investment in proprietary development in 2011

Other Expenses

FY2011: Balance Sheet

in € million	2011	2010
Assets
Cash, Cash Equivalents & Marketable Securities	134.4	108.4
Other Current Assets	20.3	24.1
Total Non-Current Assets	73.7	77.3
Total Assets	228.4	209.8
Liabilities & Stockholders' Equity
Total Current Liabilities	23.8	21.4
Total Non-Current Liabilities	7.5	2.5
Total Stockholders' Equity	197.1	185.9
Total Liabilities & Stockholders' Equity	228.4	209.8

MorphoSys's Shareholder Base

Guidance 2012

in € million	2012	2011
Group Revenues	75 – 80	100.8
Investment into Proprietary R&D	20 – 25	36.7
Group EBIT	1 – 5	11.1

in € million	2012	2011
AbD Serotec Segment Revenues (at constant currency)	20 – 22	19.3
AbD Serotec EBIT Margin (at constant currency)	~ 6% – 8%	5%

How to Look at MorphoSys?

Outlook 2012

Outlook 2012

Own Clinical Programs to Advance Significantly in 2012

The Partnered Pipeline What's Coming Up?

Expected dates for completion of clinical trials (MorphoSys estimates)

Visibility on Pipeline Value Increases Constantly

Outlook 2012

Other Items to Watch Out For

to market

Q&A Session

Thank You